Defects in specific lipoprotein lipase components (LPLC-I and LPLC-II) may play an etiological role in type I and type III primary hyperlipoproteinemias.
Answers are grounded in this paper and cite their sources.
LPL activation defects may contribute to type I/III hyperlipoproteinemia etiology; leaves open clinical relevance or need for validation.
Purified postheparin plasma lipoprotein lipase (LPL) of normolipidemic and primary hyperlipoproteinemic subjects was characterized by lipoprotein C polypeptide activation and specificity for triglycerides in chylomicrons and VLDL. Chromatography of normal LPL on Sephadex G-100 resulted in two protein peaks, LPLC-1 (activated by C-I but not C-II) and LPLC-II (activated by C-II but not C-I). LPL from type I hyperlipoproteinemic subjects was not activated by C-I and C-II activation was reduced to 40% of control. Hydrolysis of chylomicron and VLDL triglycerides was severely impaired. Although chromatography of type I LPL resulted in two protein peaks, the protein peak corresponding to LPLC-I did not exhibit lipolytic activity and LPLC-II was reduced to 50% of control in protein and enzyme specific activity. Type III LPL was normal in respect to LPLC-I while LPLC-II averaged 40% of control. Hydrolysis of chylomicron and VLDL was reduced to 50% and 10% of control, respectively. An etiological implication for LPLC-I and/or LPLC-II in type I and III hyperlipoproteinemias is suggested.
No takes yet. Share an insight, caveat, or question.
Ganesan et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: